Pages that link to "Q42545586"
Jump to navigation
Jump to search
The following pages link to Comparative Effects of Topical Ocular Anti-Allergy Drugs on Human Conjunctival Mast Cells (Q42545586):
Displaying 34 items.
- Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles. (Q33253499) (← links)
- Nedocromil sodium: a review of the evidence for a dual mechanism of action (Q33863949) (← links)
- Conjunctival cytokines in ocular allergy (Q34039956) (← links)
- Ocular mast cells. Characterization in normal and disease states (Q34249346) (← links)
- A review of plant species used to treat conjunctivitis (Q34504525) (← links)
- Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells (Q34523406) (← links)
- Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models (Q34542223) (← links)
- The role of histamine in allergic disease: re-appraisal of its inflammatory potential (Q34572463) (← links)
- The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation (Q34595167) (← links)
- The central role of conjunctival mast cells in the pathogenesis of ocular allergy (Q34666591) (← links)
- Ocular allergy guidelines: a practical treatment algorithm (Q34730735) (← links)
- Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety (Q35411434) (← links)
- Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease (Q35773063) (← links)
- A review of the use of olopatadine in allergic conjunctivitis (Q36104875) (← links)
- Emerging drugs for ocular allergy (Q36219638) (← links)
- Ocular allergy in pediatric practice (Q36527874) (← links)
- Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. (Q37716013) (← links)
- Antihistamines in Ocular Allergy: Are They All Created Equal? (Q37857745) (← links)
- Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. (Q38040514) (← links)
- Advances in pharmacotherapy for allergic conjunctivitis (Q38460976) (← links)
- Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops (Q39956528) (← links)
- Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2 -mobilization and cytokine release from human corneal epithelial cells (Q41768494) (← links)
- Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models (Q42138353) (← links)
- Pharmacology, clinical efficacy and safety of olopatadine hydrochloride (Q43061719) (← links)
- Allergic eye disease mechanisms (Q43095204) (← links)
- Cost-effectiveness of olopatadine in seasonal allergic conjunctivitis treatment (Q43266406) (← links)
- Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells (Q43813384) (← links)
- Interactions of olopatadine and selected antihistamines with model and natural membranes (Q44713017) (← links)
- Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study (Q45100818) (← links)
- Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge (Q46846459) (← links)
- Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2. (Q64990019) (← links)
- Olopatadine inhibits TNFalpha release from human conjunctival mast cells (Q73833429) (← links)
- A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model (Q74180768) (← links)
- Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction (Q83352511) (← links)